CerbB2、ER、PR、Ki67在乳腺癌中的表达及其意义  

Expressions and clinical significances of CerbB2,ER,PR and Ki67 in breast cancer

作　　者：韩冬艳[1] 朱延波[1] 蒋虹伟[1] 

机构地区：[1]同济大学附属第十人民医院病理科,上海200072

出　　处：《武警医学院学报》2012年第2期85-87,91,共4页Acta Academiae Medicinae CPAPF

基　　金：同济大学青年优秀人才培养计划资助(项目编号:2009KJ010)

摘　　要：【目的】联合检测CerbB2、ER、PR、Ki67在乳腺浸润性导管癌中的表达并探讨相关临床意义。【方法】采用免疫组化方法分别检测124例乳腺癌组织中CerbB2、ER、PR和Ki67的表达。【结果】124例乳腺癌CerbB2、ER、PR和Ki67阳性表达率分别为44.35%、65.32%、46.77%、83.06%。在不同肿瘤大小及患者年龄组间,CerbB2、ER、PR、Ki67的阳性表达率均无显著性差异(P>0.05),四者阳性表达与组织学分级的差异均具有显著性(P<0.05);另外,在有、无腋窝淋巴结转移组间,CerbB2、PR、Ki67的阳性表达均具有显著性差异(P<0.05)。【结论】联合检测CerbB2、ER、PR、Ki67的表达有助于判断乳腺癌的生物学行为及预后,并指导内分泌及靶向治疗。【Objective】To detect the expressions of CerbB2,ER,PR,Ki67 in invasive ductal carcinoma and study its clinical significances.【Methods】 Expressions of CerbB2,ER,PR,Ki67 in 124 invasive ductal carcinoma were detected by immunohistochemistry technique.【Results】 The rate of positive expressions of CerbB2,ER,PR,Ki67 were 44.35%,65.32%,46.77%,and 83.06% respectively.There were no significant difference in CerbB2,ER,PR,Ki67 positive expression rate In different tumor size and patient age groups（P 〉 0.05）.The differences in histology phase were statistically significant（P 〈 0.05）.Furthermore,the positive expressions of CerbB2,PR,Ki67 in lymphatic metastasis and without lymphatic metastasis groups were significant difference（P 〈 0.05）.【Conclusions】Combined detection of the expressions of CerbB2,ER,PR,Ki67 maybe helpful to determining the biological behavior and prognosis of breast cancer,and guiding the endocrine and targeted therapy.

关 键 词：乳腺肿瘤 免疫组织化学 预后 

分 类 号：R541.4[医药卫生—心血管疾病]